Veratraldehyde

We are Veratraldehyde CAS:120-14-9 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests


Product Name: Veratraldehyde
Synonym: 3,4-Dimethoxybenzaldehyde; Vanilline methyl ether
Cas No.: 120-14-9
Formula: C₉H₁₀O₃
MW: 166.17
EINECS No.: 204-373-2

HS Code: 2912299000

UN No.: 2923
Hazard class: 8 categories 
Packing level: Class III
 
Specification

Application
Veratraldehyde is an organic compound that is widely used as a flavorant and odorant.
Applicationd by the pharmaceutical industry to synthesize methyldopa.
Also used in the production of veterinary drug sulfonamide synergist.
For the synthesis of antibiotic drugs.
 
Packaging
25 kg/barrel, can also be packaged according to customer requirements. 
 
Storage
Store in a cool, ventilated warehouse. 
Keep away from fire and heat. 
The temperature should not exceed 37 °C. 




Related News: European companies are the main suppliers of specialty APIs, but due to environmental and cost pressures, APIs have begun to shift to the Asian market.154748-67-1 European companies are the main suppliers of specialty APIs, but due to environmental and cost pressures, APIs have begun to shift to the Asian market.3-hidroxi-4,4,4-trifluorobutirato de etilo CAS:372-30-5 As one of the world’s largest API producers and exporters, China’s chemical API production and operating income show steady growth.Poli [trifluoropropil (metil) siloxano] CAS:63148-56-1 Profitability continued to improve. The company’s comprehensive gross profit margin for the first three quarters was 36.06%, a year-on-year increase of 3.44 percentage points. Since this year, the company’s profitability has remained at a relatively high level. On the one hand, due to the decline in the trading business with lower profitability, the proportion has declined.Pre-approval Access Programs (also known as expanded access, early access, compassionate use, named patient supply) are regulatory-compliant processes permitting experimental agents in development to be made available upon the request of a physician or a patient for appropriate patients for whom no alternative treatment option exists in their country.